Pasar al contenido principal

REGULACION DE LA TRANSCRIPCION POR ENHANCERS Y SILENCIADORES EN UN GENOMA TRIDIMENTIONAL

PID2023-149538NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma

  • Zarzuela, Laura
  • López-Cepero, Ignacio G.
  • Rattigan, Kevin M.
  • Reina-Bando, Ana
  • Martín-Montalvo, Jorge
  • Sierra-Párraga, Jesús M.
  • Sánchez-Escabias, Elena
  • Morillo-Huesca, Macarena
  • Oltra, Sara S.
  • Ceballos-Chávez, María
  • Capilla-González, Vivian
  • Moreno-Bueno, Gema
  • Murdoch, Piedad del Socorro
  • Reyes, José C.
  • Helgason, G. Vignir
  • Tomé, Mercedes
  • Durán, Raúl V.
Therapy resistance is a major limitation in therapeutic efficacy for glioblastoma (GBM) patients, positioning GBM among the deadliest tumor types. In this work, we have dissected resistance mechanisms in GBM, which resulted in the identification of FGFR1 pathway as a major controller of the signaling and metabolic rewiring associated to temozolomide (TMZ) resistance. Hence, in FGFR1-positive, p53 WT GBM cells, FGFR1 controls a p53-mediated cell cycle arrest to allow DNA repair in response to TMZ. FGFR1 also regulates a complete metabolic rewiring promoting lipid catabolism and preventing lipid peroxidation. Indeed, FGFR1 inhibition completely abolishes this signaling and metabolic reprograming, restoring sensitivity to TMZ. Our results also indicated a correlation of FGFR1 with poor prognosis in GBM patients, and validated the dual treatment with TMZ and FGFR1 inhibitors as an efficient strategy to induce tumor cell death in FGFR1-positive, p53 WT pre-clinical animal GBM models. These data position FGFR1 as a promising candidate for future clinical evaluation to limit therapy resistance to TMZ in FGFR1-positive GBM patients., Grants PID2021-124251OB-I00 and PID2024-156338OB-I00 funded by the Spanish MICIU/AEI/10.13039/501100011033/and by ERDF/EU (RVD, MTM). Grant RED2022-134927-T funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU (RVD, MTM) Grant PID2023-149538NB-I00 funded by the Spanish MICIU/AEI/10.13039/501100011033/and by ERDF/EU (JCR). Predoctoral FPU contract (FPU19/04914) from the Spanish Ministry of Universities (LZM). Predoctoral contract (PREDOC_00345) funded by PAIDI, Junta de Andalucia (IGLC). Predoctoral FPI contract (PRE2022-101357) funded by Spanish MICIU/AEI/10.13039/501100011033 and FSE+ (ARB). Predoctoral contract (PRDSE258639MART) from Asociación Española Contra el Cáncer (JMM). Grant PI23/00315 funded by Spanish Institute of Health Carlos III, co funded by Fondos FEDER (VCG). Grant CD23/00104 funded by Spanish Institute of Health Carlos III, co funded by Fondos FEDER (JMSP). Grant RyC2023-043933-I funded by Spanish Ministerio de Ciencia, Innovacion y Universidades (VCG). Grant A29754 funded by Cancer Research UK, UK (GVH). Grant CB16/12/00295 funded by Spanish CIBERONC (GMB). Grant PID2022-136854OB-I00 funded by MICIU/AEI/10.13039/501100011033 (GMB)., Peer reviewed